Company Overview

Alexandria Real Estate Equities, Inc. (NYSE: ARE) is a U.S.-based real estate investment trust (REIT) focused primarily on owning, operating, and developing collaborative life science, agtech, and advanced technology campuses. The company operates at the intersection of commercial real estate and scientific innovation infrastructure, serving biotechnology companies, pharmaceutical firms, academic research institutions, medical technology businesses, and government-related research organizations. ARE is widely recognized for specializing in laboratory and research environments that require highly technical infrastructure, differentiated regulatory compliance capabilities, and proximity to leading innovation ecosystems.

The company’s principal revenue drivers are rental income from long-term leases, property development activities, and strategic real estate investments tied to innovation clusters. ARE has developed a concentrated presence in major life science markets including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, and Research Triangle. Founded in 1994 by Joel S. Marcus, the company evolved from a niche life science landlord into one of the largest dedicated life science REITs in the United States through disciplined campus development, strategic acquisitions, and partnerships with research-driven tenants and institutions.

Business Operations

ARE conducts business primarily through its consolidated operating partnership, Alexandria Real Estate Equities, L.P., and organizes operations around owning and developing Class A laboratory and office campuses designed for scientific research and innovation. The company generates most of its revenue through leasing laboratory, office, and specialized research space to tenants operating in biotechnology, pharmaceutical development, diagnostics, artificial intelligence-enabled healthcare, and related sectors. Its portfolio includes integrated campuses featuring laboratory infrastructure, collaborative amenities, incubator facilities, and technology-enabled environments intended to support tenant innovation ecosystems.

The company’s operations are concentrated in key U.S. innovation clusters, though many tenants are multinational organizations with global research footprints. ARE controls significant development assets, entitled land positions, and specialized laboratory infrastructure that create barriers to entry in highly regulated scientific real estate markets. Strategic relationships with universities, healthcare systems, venture capital firms, and research institutions support tenant acquisition and long-term occupancy. ARE has also maintained investment relationships and venture-oriented ecosystem partnerships associated with life science innovation and early-stage scientific enterprises.

Strategic Position & Investments

ARE’s strategic direction centers on expanding high-demand life science campuses in supply-constrained innovation markets while maintaining long-term relationships with investment-grade and research-oriented tenants. The company has consistently invested in large-scale development and redevelopment projects near leading academic and medical institutions, emphasizing locations where scientific talent, venture capital, and research funding are concentrated. ARE’s strategy prioritizes recurring rental income, long lease durations, and high tenant retention rates within specialized laboratory environments that are difficult and costly to replicate.

The company has pursued acquisitions of laboratory properties and development sites to strengthen its position in core clusters, while also investing in innovation infrastructure supporting emerging sectors such as cell therapy, genomics, artificial intelligence in healthcare, and advanced therapeutics. ARE has participated in venture ecosystem initiatives and collaborative innovation programs connected to life sciences commercialization. Notable strategic assets include premier urban and campus-style developments across Greater Boston, South San Francisco, San Diego, and New York City, where proximity to research institutions and biotechnology capital markets supports long-term demand.

Geographic Footprint

ARE’s headquarters are located in Pasadena, California, and the company maintains a concentrated but nationally significant footprint across leading U.S. innovation hubs. Its primary operating regions include Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. These markets are among the largest recipients of biotechnology venture funding, NIH research grants, and pharmaceutical R&D investment in the United States.

The company’s portfolio strategy emphasizes dense clustering within established scientific ecosystems rather than broad international expansion. While ARE’s owned assets are primarily U.S.-based, its tenant roster includes multinational pharmaceutical and biotechnology companies conducting globally connected research and commercialization activities. ARE’s operational influence is therefore tied closely to globally significant innovation corridors and research markets that attract international scientific investment and talent.

Leadership & Governance

ARE was founded by Joel S. Marcus, who served for many years as chairman and chief executive officer and played a central role in establishing the modern life science REIT sector. The company’s leadership strategy has historically emphasized long-term capital allocation, innovation-cluster concentration, scientific ecosystem development, and disciplined balance sheet management. Public filings and investor communications describe a governance philosophy centered on strategic real estate specialization, tenant quality, and long-duration value creation.

Key executives include:

• Peter M. Moglia – Chief Executive Officer
• Joel S. Marcus – Executive Chairman
• Daniel J. Ryan – Co-President and Regional Market Director
• Stephen Richardson – Co-President and Chief Operating Officer
• Thomas J. Andrews – Chief Investment Officer
• Dean A. Shigenaga – Chief Financial Officer

Leadership and operational information has been verified against publicly available materials including SEC filings, annual reports, earnings materials, and investor presentations. Where executive roles or organizational structures vary across reporting periods, the most recently disclosed public information has been prioritized.